No takes yet. Share an insight, caveat, or question.
Narrative review highlights molecular mechanisms and mTOR pathway alterations in PEComas, indicating potential clinical efficacy for rapamycin in malignant tumors.
Martignoni et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: